Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels.

Journal for Immunotherapy of Cancer
Javier Ramos-ParadasLuis Paz-Ares

Abstract

Tumor mutational burden (TMB) is a recently proposed predictive biomarker for immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available assays for TMB determination differ in horizontal coverage, gene content and algorithms, leading to discrepancies in results, impacting patient selection. A harmonization study of TMB assessment with available assays in a cohort of patients with NSCLC is urgently needed. We evaluated the TMB assessment obtained with two marketed next generation sequencing panels: TruSight Oncology 500 (TSO500) and Oncomine Tumor Mutation Load (OTML) versus a reference assay (Foundation One, FO) in 96 NSCLC samples. Additionally, we studied the level of agreement among the three methods with respect to PD-L1 expression in tumors, checked the level of different immune infiltrates versus TMB, and performed an inter-laboratory reproducibility study. Finally, adjusted cut-off values were determined. Both panels showed strong agreement with FO, with concordance correlation coefficients (CCC) of 0.933 (95% CI 0.908 to 0.959) for TSO500 and 0.881 (95% CI 0.840 to 0.922) for OTML. The corresponding CCCs were 0.951 (TSO500-FO) and 0.919 (OTML-FO) in tumors with <1% of cells expressing PD-L1 (...Continue Reading

References

Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Apr 16, 2016·Nature Reviews. Cancer·Suzanne L TopalianDrew M Pardoll
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Dec 8, 2016·The Lancet Oncology·Geoffrey T GibneyMichael B Atkins
Apr 20, 2017·Genome Medicine·Zachary R ChalmersGarrett M Frampton
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Oct 21, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Reinhard BüttnerMing-Sound Tsao
Apr 17, 2018·The New England Journal of Medicine·Matthew D HellmannLuis Paz-Ares
May 26, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ming Sound TsaoFred R Hirsch
Sep 22, 2018·International Journal of Cancer. Journal International Du Cancer·Ivo BuchhalterAlbrecht Stenzinger
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Nov 6, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T A ChanS Peters
Dec 7, 2018·Translational Lung Cancer Research·John TruesdellDavid Fabrizio
Feb 23, 2019·ESMO Open·Reinhard BüttnerFrédérique Penault-Llorca
Sep 29, 2019·The New England Journal of Medicine·Matthew D HellmannSuresh S Ramalingam
Mar 3, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Albrecht StenzingerManfred Dietel
Mar 25, 2020·The Journal of Molecular Diagnostics : JMD·Leonie I KroezeMarjolijn J L Ligtenberg
May 26, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Simon HeekePaul Hofman
May 28, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckMark A Socinski
Jun 12, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Lynette M ShollJohn W Longshore

❮ Previous
Next ❯

Citations

Oct 15, 2021·Frontiers in Cell and Developmental Biology·Bo DongYu Qi

❮ Previous
Next ❯

Software Mentioned

OTML
WES

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.